CAJ | 학술논문

目的：评价Rho激酶抑制剂对急性ST段抬高心肌梗死（STEMI）患者行急诊经皮冠状动脉介入治疗（PCI）冠脉血流的影响。方法拟行急诊PCI术STEMI患者66例（均于发病12h内）随机分为治疗组及对照组各33例；两组均予严格冠心病二级预防；治疗组术前20min开始使用法舒地尔并继续使用至病程1周，主要观察患者PCI术中TIMI血流分级和心肌组织灌注，住院期间肌钙蛋白（cTNI）、肌酸激酶同功酶（CKMB）、超声心动图、主要不良心血管事件（MACE）、低血压发生情况。结果治疗组6例患者出现低血压停用法舒地尔；两组患者TIMI血流分级、校正的TIMI帧数计数（CTFC）、CKMB、cTNI、左室收缩功能差异有统计学意义（P=0.039、0.045、0.028、0.049）；住院期间MACE、出血、低血压等发生率差异无统计学意义。结论在STEMI患者急诊PCI术中，常规治疗基础上应用Rho激酶抑制剂可改善冠脉血流。
목적：평개Rho격매억제제대급성ST단태고심기경사（STEMI）환자행급진경피관상동맥개입치료（PCI）관맥혈류적영향。방법의행급진PCI술STEMI환자66례（균우발병12h내）수궤분위치료조급대조조각33례；량조균여엄격관심병이급예방；치료조술전20min개시사용법서지이병계속사용지병정1주，주요관찰환자PCI술중TIMI혈류분급화심기조직관주，주원기간기개단백（cTNI）、기산격매동공매（CKMB）、초성심동도、주요불양심혈관사건（MACE）、저혈압발생정황。결과치료조6례환자출현저혈압정용법서지이；량조환자TIMI혈류분급、교정적TIMI정수계수（CTFC）、CKMB、cTNI、좌실수축공능차이유통계학의의（P=0.039、0.045、0.028、0.049）；주원기간MACE、출혈、저혈압등발생솔차이무통계학의의。결론재STEMI환자급진PCI술중，상규치료기출상응용Rho격매억제제가개선관맥혈류。
Objective To evaluate the efficacy and safety of the patients with acute ST-elevation myocardial infarction (STEMI) use Rho-kinase inhibitor in primary percutaneous coronary intervention (PCI). Methods 66 patients with STEMI ( both in the incidence of the 12-hour period) ready to receive primary PCI were randomly divided into two groups:control group(non-use of fasudil hydrochloride, n=33), fasudil hydrochloride group (intravenous infusion, n=33); the thrombolysis in myocardial infarction(TIMI) grade and corrected TIMI frame count(CTFC) were observed in PCI process, peak serum CKMB and cTNI levels, left ventricular ejection fraction(LVEF), hemorrhage event ,thrombocytopenia, low blood pressure and major adverse cardiovascular event (MACE) were also studied during hospital. Results The two groups with CTFC, CKMB, cTNI and LVEF were statistically significant(P=0.039, 0.045, 0.028, 0.049, respectively);TIMI grade, hospital MACE, low blood pressure, hemorrhage event and thrombocytopenia were no significant difference. Conclusion Application of fasudil hydrochloride during primary PCI in STEMI patients were safe and effective, which can improve myocardial perfusion.